An infrequent relapse of multiple myeloma predominantly manifesting as light chain escape: Clinical experience from two Chinese centers

Leukemia and Lymphoma

Volumn 51, Issue 10, 2010, Pages 1844-1849

  Qu, Xiaoyan ^a   Zhang, Li ^b   Fu, Weijun ^a   Zhang, Hui ^a   Xiang, Xixi ^a   Qiu, Lugui ^b   Hou, Jian ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

intact immunoglobulins; light chain escape; Multiple myeloma; prognosis

Indexed keywords

BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; MELPHALAN; PREDNISOLONE; THALIDOMIDE; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BIOLOGICAL THERAPY; CANCER RELAPSE; CELL STRUCTURE; CHINESE; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; OVERALL SURVIVAL; PLASMA CELL; PRIORITY JOURNAL; PROTEIN URINE LEVEL;

ADULT; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMA CELLS; RECURRENCE; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 77957731372     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.506933     Document Type: Article

References (10)

1. Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child JA, Bradwell AR. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004;126:348-354.
2. Hobbs JR. Growth rates and responses to treatment in human myelomatosis. BrJHaematol 1969;16:607-617.
3. Dawson MA, Patil S, Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica 2007; 92:143-144.
4. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473.
5. Kuhnemund A, Liebisch P, Bauchmuller K, et al. 'Light-chain escape-multiple myeloma'-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. J Cancer Res Clin Oncol 2009;135:477-484.
6. Nowrousian MR, Brandhorst D, Sammet C, et al. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Cancer Res 2005; 11:8706-8714.
7. Balleari E, Ghio R, Falcone A, Musto P. Possible multiple myeloma dedifferentiation following thalidomide therapy: a report of four cases. Leuk Lymphoma 2004;45: 735-738.
8. Pirrotta MT, Gozzetti A, Cerase A, et al. Unusual discordant responses in two multiple myeloma patients during bortezo-mib treatment. Onkologie 2008;31:45-47.
9. Magrangeas F, Cormier ML, Descamps G, et al. Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level. Blood 2004;103:3869-3875.
10. Ayliffe MJ, Davies FE, de Castro D, Morgan GJ. Demonstra-tion of changes in plasma cell subsets in multiple myeloma. Haematologica 2007;92:1135-1138.